Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Nov;4(11):1397-403.
doi: 10.1097/JTO.0b013e3181ba2f1d.

Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

Daniel D Karp  1 , Michael N Pollak, Roger B Cohen, Peter D Eisenberg, Paul Haluska, Donghua Yin, Allan Lipton, Laurence Demers, Kim Leitzel, Mary L Hixon, Leon W Terstappen, Linda Garland, Luis G Paz-Ares, Felipe Cardenal, Corey J Langer, Antonio Gualberto
Affiliations
Clinical Trial

Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

Daniel D Karp et al. J Thorac Oncol. 2009 Nov.

Abstract

Introduction: This phase 1 study was conducted to determine the recommended phase 2 dose of the selective insulin-like growth factor type 1 receptor (IGF-IR) inhibitor figitumumab (F, CP-751,871) given in combination with paclitaxel and carboplatin in patients with advanced solid tumors.

Methods: Patients received paclitaxel 200 mg/m2, carboplatin (area under the curve of 6), and F (0.05-20 mg/kg) q3 weeks for up to six cycles. Patients with objective response or stable disease were eligible to receive additional cycles of single agent F until disease progression. Safety, efficacy, pharmacokinetic, and pharmacodynamic endpoints were investigated.

Results: Forty-two patients, including 35 with stages IIIB and IV non-small cell lung cancer (NSCLC), were enrolled in eight dose escalation cohorts. A maximum tolerated dose was not identified. Severe adverse events possibly related to F included fatigue, diarrhea, hyperglycemia, gamma glutamyl transpeptidase elevation, and thrombocytopenia (one case each). F plasma exposure parameters increased with dose. Fifteen objective responses (RECIST) were reported, including two complete responses in NSCLC and ovarian carcinoma. Notably, levels of bioactive IGF-1 seemed to influence response to treatment with objective responses in patients with a high baseline-free IGF-1 to IGF binding protein-3 ratio seen only in the 10 and 20 mg/kg dosing cohorts.

Conclusions: F was well tolerated in combination with paclitaxel and carboplatin. Based on its favorable safety, pharmacokinetic, and pharmacodynamic properties, the maximal feasible dose of 20 mg/kg has been selected for further investigation.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Mean (±SD) plasma concentration-time profiles of figitumumab (F) after cycles 1 and 3 of treatment.
FIGURE 2
FIGURE 2
Time profiles of circulating endothelial cell (CEC) counts in (A) all patients with providing samples for CEC enumeration (N = 22) and (B) according to figitumumab (F) treatment doses ≤6 mg/kg (N = 12) or 10 to 20 mg/kg (N = 10). Data are represented as box plots (minimum, 25 percentile, median, 75 percentile, maximum) and individual CEC counts. Values outside the box plots are considered outliers (smaller or larger than the minimum or maximum estimates).
FIGURE 3
FIGURE 3
Soluble insulin-like growth factor type 1 receptor (IGF-1R) extracellular domain (sIGF-1R), IGF binding protein-3 (IGFBP-3), and free IGF-1 (fIGF-1) levels by figitumumab (F) dose. Data are represented relative to baseline levels.
FIGURE 4
FIGURE 4
Analysis of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3), free IGF-1 (fIGF-1) levels, and fIGF-1/IGFBP-3 ratio in responders(R) and nonresponders (NR) to treatment, according to RECIST, at figitumumab (F) treatment doses ≤6 mg/kg (N = 18) or 10 to 20 mg/kg (N = 22).
See this image and copyright information in PMC

References

    1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928. - PubMed
    1. Favoni RE, De Cupis A, Ravera F, et al. Expression and function of the insulin like growth factor 1 system in human non small cell lung cancer and normal lung cell lines. Int J Cancer. 1994;56:858–866. - PubMed
    1. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum Insulin like growth factor (IGF) and IGF binding protein levels and risk of lung cancer: a case control study nested in the beta carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev. 2002;11:1413–1418. - PubMed
    1. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody figitumumab. Clin Cancer Res. 2005;11:2063–2073. - PubMed
    1. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–6309. - PubMed

Publication types

MeSH terms